EGFR and non-small cell lung carcinoma: Although gefitinib and erlotinib are effective in treating NSCLC with EGFR-sensitive mutations, patients develop drug resistance within an average of 9 to 14 months after treatment, severely limiting the clinical use of first-generation inhibitors [106,109,110,111].